A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors

Scot Ebbinghaus, Eric Rubin, Evan Hersh, Lee D. Cranmer, Peter L. Bonate, Robert J. Fram, Antti Jekunen, Steve Weitman, Lisa A. Hammond

Research output: Contribution to journalArticlepeer-review

38 Scopus citations

Fingerprint

Dive into the research topics of 'A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors'. Together they form a unique fingerprint.

Medicine & Life Sciences